Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
Total Valuation
C4 Therapeutics has a market cap or net worth of $110.77M. The enterprise value is $75.03M.
Market Cap$110.77M
Enterprise Value$75.03M
Share Statistics
C4 Therapeutics has 71,007,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,007,080
Owned by Insiders3.13%
Owned by Institutions0.33%
Financial Efficiency
C4 Therapeutics’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -41.42%.
Return on Equity (ROE)-0.54
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-41.42%
Return on Capital Employed (ROCE)-0.42
Revenue Per Employee188.69K
Profits Per Employee-1.20M
Employee Count110
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of C4 Therapeutics is -2.12. C4 Therapeutics’s PEG ratio is -0.69.
PE Ratio-2.12
PS Ratio4.23
PB Ratio1.14
Price to Fair Value1.14
Price to FCF-2.58
Price to Operating Cash Flow-2.63
PEG Ratio-0.69
Income Statement
In the last 12 months, C4 Therapeutics had revenue of 20.76M and earned -132.49M in profits. Earnings per share was -2.67.
Revenue20.76M
Gross Profit-96.95M
Operating Income-139.03M
Pretax Income-131.21M
Net Income-132.49M
EBITDA-122.10M
Earnings Per Share (EPS)-2.67
Cash Flow
In the last 12 months, operating cash flow was -65.16M and capital expenditures -180.00K, giving a free cash flow of -65.34M billion.
Operating Cash Flow-65.16M
Free Cash Flow-65.34M
Free Cash Flow per Share-0.92
Dividends & Yields
C4 Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.50
52-Week Price Change-75.12%
50-Day Moving Average2.09
200-Day Moving Average4.43
Relative Strength Index (RSI)49.30
Average Volume (3m)1.05M
Important Dates
C4 Therapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
C4 Therapeutics as a current ratio of 6.34, with Debt / Equity ratio of 30.44%
Current Ratio6.34
Quick Ratio6.34
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio-101.26
Taxes
In the past 12 months, C4 Therapeutics has paid 1.28M in taxes.
Income Tax1.28M
Effective Tax Rate>-0.01
Enterprise Valuation
C4 Therapeutics EV to EBITDA ratio is -1.84, with an EV/FCF ratio of -2.07.
EV to Sales10.83
EV to EBITDA-1.84
EV to Free Cash Flow-2.07
EV to Operating Cash Flow-2.10
Balance Sheet
C4 Therapeutics has $244.90M in cash and marketable securities with $69.72M in debt, giving a net cash position of -$179.15M billion.
Cash & Marketable Securities$244.90M
Total Debt$69.72M
Net Cash-$179.15M
Net Cash Per Share-$2.52
Tangible Book Value Per Share$4.96
Margins
Gross margin is 82.78%, with operating margin of -669.84%, and net profit margin of -638.34%.
Gross Margin82.78%
Operating Margin-669.84%
Pretax Margin-632.17%
Net Profit Margin-638.34%
EBITDA Margin-588.28%
EBIT Margin-625.55%
Analyst Forecast
The average price target for C4 Therapeutics is $11.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.88
Price Target Upside637.89% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast71.44%
EPS Growth Forecast43.22%